

FcRn Column - 文献リスト

1. Alt, N., et al. (2016) Determination of critical quality attributes for monoclonal antibodies using quality by design principles, *Biologicals* 44(5), 291 – 305
2. Cymer, F., et al. (2017) Evaluation of an FcRn affinity chromatographic method for IgG1-type antibodies and evaluation of IgG variants, *Bioanalysis* 9(17), 1305 – 1317
3. Datta-Mannan, A., et al. (2014) Application of FcRn binding assays to guide mAb development, *Drug Metab Dispos* 42(11), 1867 – 1872
4. Dostalek, M., et al. (2017) Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates, *MAbs* 9(5), 756 – 766
5. Edelmann, M. R., et al. (2019) Radiolabeled IgG antibodies: Impact of various labels on neonatal Fc receptor binding, *J Labelled Comp Radiopharm* 62(11), 751 – 757
6. Edelmann, M. R., et al. (2021) Functional in vitro assessment of modified antibodies: Impact of label on protein properties, *PLoS One* 16(9), e0257342
7. Gahoual, R., et al. (2017) Detailed Characterization of Monoclonal Antibody Receptor Interaction Using Affinity Liquid Chromatography Hyphenated to Native Mass Spectrometry, *Anal Chem* 89(10), 5404 – 5412
8. Habegger, M., et al. (2015) Functional assessment of antibody oxidation by native mass spectrometry, *MAbs* 7(5), 891 – 900
9. Jensen, F. P., et al. (2017) A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life, *Mol Cell Proteomics* 16(3), 451 – 456
10. Jensen, P. F., et al. (2015) Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry, *Mol Cell Proteomics* 14(1), 148 – 161
11. Neuber, T., et al. (2014) Characterization and screening of IgG binding to the neonatal Fc receptor, *MAbs* 6(4), 928 – 942
12. Piche-Nicolas, N. M., et al. (2018) Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics, *MAbs* 10(1), 81 – 94
13. Pyzik, M., et al. (2019) The Neonatal Fc Receptor (FcRn): A Misnomer?, *Front Immunol* 10, 1540
14. Robbie G. J., et al. (2013) A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults, *Antimicrob Agents Chemother* 57(12), 6147 – 6153
15. Roopenian, D. C., et al. (2007) FcRn: the neonatal Fc receptor comes of age, *Nature Rev Immunol* 7(9), 715 – 725

16. Schlothauer, T., et al. (2013) Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies, *MAbs* 5(4), 576 – 586
17. Schoch, A., et al. (2015) Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics, *Proc Natl Acad Sci USA* 112(19), 5997 – 6002
18. Sounders, C. A., et al. (2015) A novel in vitro assay to predict neonatal Fc receptor mediated human IgG half-life, *MAbs* 7(5), 912 – 921
19. Stracke, J., et al. (2014) A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies, *MAbs* 6(5), 1229 – 1242
20. Suzuki, T., et al. (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR, *J Immunol* 184(4), 1968 – 1976
21. Walters, B. T., et al. (2016) Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc Receptor, *J Biol Chem* 291(4), 1817 – 1825
22. Wang, W., et al. (2011) Impact of methionine oxidation in human IgG1 Fc on serum half life of monoclonal antibodies, *Mol Immunol* 48(6-7), 860 – 866
23. Wang, W., et al. (2011) Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences, *Drug Metab Dispos* 39(9), 1469 – 1477
24. Wang, X., et al. (2017) Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data, *MAbs* 9(2), 319 – 332
25. Wang, Y., et al. (2014) Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering, *L Drug Target* 22(4), 269 – 278
26. Victoria C., et al (2023) A generic platform to couple affinity chromatography with native mass, *J. Pharm. Biomed. Anal.* 228 (2023) 115337
27. Maximilian B., et al (2022) The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement, *Nature, Nature Communications* | (2022) 13:6073
28. Saitoh Satoshi (2018), The Identification of Critical Quality Attributes (CQAs) for the Development of Antibody Drugs, *YAKUGAKU ZASSHI* 138, 1475-1481 (2018)